, Tracking Stock Market Picks
Enter Symbol:
Biocryst Pharmaceuticals, Inc. (BCRX) [hlAlert]

up 8.94 %

Biocryst Pharmaceuticals, Inc. (BCRX) rated Buy with price target $14 by Needham

Posted on: Tuesday,  Feb 18, 2014  8:25 AM ET by Needham

Needham rated Buy Biocryst Pharmaceuticals, Inc. (NASDAQ: BCRX) on 02/18/2014, when the stock price was $10.29. Since
then, Biocryst Pharmaceuticals, Inc. has gained 8.94% as of 01/25/2016's recent price of $11.21.
If you would have followed this Needham's recommendation on BCRX, you would have gained 8.94% of your investment in 706 days.

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.

Needham & Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham & Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/18/2014 8:25 AM Buy
10.29 14.00
as of 10/17/2014
1 Week up  11.02 %
1 Month up  2.47 %
3 Months up  8.12 %
1 YTD up  12.53 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy